Apnimed (NASDAQ:APMD) Upgraded to “Hold” at Zacks Research

Apnimed (NASDAQ:APMD) was upgraded by investment analysts at Zacks Research to a “hold” rating in a report released on Wednesday,Zacks.com reports.

APMD has been the subject of a number of other reports. Wall Street Zen raised Apnimed to a “hold” rating in a research note on Saturday, August 8th. Bank of America started coverage on shares of Apnimed in a research report on Tuesday. They set a “buy” rating and a $41.00 price target on the stock. Cantor Fitzgerald began coverage on Apnimed in a research note on Tuesday. They set an “overweight” rating and a $60.00 price objective on the stock. Evercore initiated coverage on Apnimed in a research note on Tuesday. They issued an “outperform” rating for the company. Finally, Lifesci Capital started coverage on Apnimed in a report on Tuesday. They set an “outperform” rating and a $50.00 price objective on the stock. Four investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Apnimed presently has an average rating of “Moderate Buy” and a consensus price target of $50.33.

Apnimed Price Performance

Shares of Apnimed stock opened at $28.72 on Wednesday. Apnimed has a fifty-two week low of $16.12 and a fifty-two week high of $35.29.

Insider Transactions at Apnimed

In other news, major shareholder Morningside Venture Investment bought 312,500 shares of the stock in a transaction on Monday, August 3rd. The stock was purchased at an average price of $16.00 per share, for a total transaction of $5,000,000.00. Following the acquisition, the insider owned 7,152,713 shares in the company, valued at approximately $114,443,408. This trade represents a 4.57% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Apnimed Company Profile

Apnimed Inc is a late stage clinical pharmaceutical company dedicated to the discovery, development and commercialization of novel oral therapies which address the neurobiology of sleep-related breathing diseases. Apnimed Inc is based in CAMBRIDGE, Mass.